drugset / Trial / NCT07579221
Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find a safe and tolerable dose of navlimetostat in combination with pumitamig that can be given to patients with MTAP-deficient advanced non-small cell lung cancer (NSCLC). The effectiveness of the study drugs will also be studied.
Timeline
- Start
- 2026-11-30
- Primary completion
- 2029-08-01
- Completion
- 2031-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986504 | Unknown | — | Oral |
| Subject | Pumitamig | Protein / enzyme biologic | — | Intravenous |